Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLARA: First-in-human BH-30643 in EGFR/HER2-mutant NSCLC
jRCT2031240718Phase 2Recruiting
- Sponsor
- BlossomHill Therapeutics
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of BH-30643 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by BlossomHill Therapeutics. Primary endpoints: Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation), Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization) and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
BH-30643
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240718.